Travere therapeutics announces presentations of abstracts at the 59th era congress

San diego, may 17, 2022 (globe newswire) -- travere therapeutics, inc. (nasdaq: tvtx) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal phase 3 protect and duplex studies of sparsentan in iga nephropathy (igan) and focal segmental glomerulosclerosis (fsgs), respectively, at the 59th european renal association (era) congress. the company and its collaborators will also present nonclinical data examining the renal protective effects of sparsentan compared to controls. era is being held live in paris, france, and virtually may 19-22, 2022.
TVTX Ratings Summary
TVTX Quant Ranking